Compare DigitalOcean Holdings Inc (DOCN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Zoetis Inc — how do they compare? DigitalOcean Holdings Inc trades at $132.66 (market cap $14.57B), while Zoetis Inc trades at $74.38 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.1× DigitalOcean Holdings Inc's market cap, and Zoetis Inc pays a 2.9% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Zoetis Inc for 70 Days on average.
| DOCN | ZTS | |
|---|---|---|
Market Cap | $14.57B | $30.20B |
Volume | 2,261,786 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $181.29 | $147.53 |
52-Week Low | $37.30 | $69.09 |
Typical Hold Time | 43 Days | 70 Days |
Enterprise Value | $15.33B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $132.70, up 4.26% today, showing strong momentum after recent earnings beats. The stock demonstrates robust fundamental performance with 29% revenue growth in Q2 2026 and impressive profitability metrics including 57.22% gross margin and 23.27% net margin. Technical indicators show bullish momentum with RSI levels suggesting potential oversold conditions, while the stock trades below the consensus price target of $172.73. Recent news highlights the company's strategic focus on AI-native cloud services with new product launches and a $725 million equipment financing facility.
DOCN presents a compelling growth story with strong AI-driven revenue acceleration and consistent earnings outperformance. However, elevated valuation multiples (P/E 56.32, P/S 13.96) and negative shareholder equity pose significant risks. The company's aggressive expansion strategy requires careful monitoring of cash flow sustainability amid substantial capital expenditures.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
